Privileged Scaffolds In Drug Discovery And Medicinal Chemistry

References

1. Welsch M.E. Snyder S.A. Stockwell B.R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol. 2010 14 3 347 361 10.1016/j.cbpa.2010.02.018 20303320
   [Google Scholar]
2. DeSimone R. Currie K. Mitchell S. Darrow J. Pippin D. Privileged structures: Applications in drug discovery. Comb. Chem. High Throughput Screen. 2004 7 5 473 493 10.2174/1386207043328544 15320713
   [Google Scholar]
3. Sravanthi T.V. Manju S.L. Indoles — A promising scaffold for drug development. Eur. J. Pharm. Sci. 2016 91 1 10 10.1016/j.ejps.2016.05.025 27237590
   [Google Scholar]
4. Musiol R. An overview of quinoline as a privileged scaffold in cancer drug discovery. Expert Opin. Drug Discov. 2017 12 6 583 597 10.1080/17460441.2017.1319357 28399679
   [Google Scholar]
5. Zhuang C. Zhang W. Sheng C. Zhang W. Xing C. Miao Z. Chalcone: A privileged structure in medicinal chemistry. Chem. Rev. 2017 117 12 7762 7810 10.1021/acs.chemrev.7b00020 28488435
   [Google Scholar]
6. Huang G. Cierpicki T. Grembecka J. 2-Aminobenzothiazoles in anticancer drug design and discovery. Bioorg. Chem. 2023 135 106477 10.1016/j.bioorg.2023.106477 36989736
   [Google Scholar]
7. Costantino L. Barlocco D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 2006 13 1 65 85 10.2174/092986706775197999 16457640
   [Google Scholar]
8. Zhao H. Dietrich J. Privileged scaffolds in lead generation. Expert Opin. Drug Discov. 2015 10 7 781 790 10.1517/17460441.2015.1041496 25959748
   [Google Scholar]
9. Huang G. Hucek D. Cierpicki T. Grembecka J. Applications of oxetanes in drug discovery and medicinal chemistry. Eur. J. Med. Chem. 2023 261 115802 10.1016/j.ejmech.2023.115802 37713805
   [Google Scholar]
10. Huang G. Cierpicki T. Grembecka J. Thioamides in medicinal chemistry and as small molecule therapeutic agents. Eur. J. Med. Chem. 2024 277 116732 10.1016/j.ejmech.2024.116732 39106658
    [Google Scholar]
11. Huang G. Cierpicki T. Grembecka J. Unlocking the potential of the thioamide group in drug design and development. Future Med. Chem. 2025 17 1 1 3 10.1080/17568919.2024.2435245 39623876
    [Google Scholar]
12. Shamim S. Alam O. Jha M. Nazar S. Mathur V. Ali S. Iliyas A. Chandra K. Jamil Ahmed S.M.A. Naim M.J. Parveen B. Triazole scaffold-based DPP-IV inhibitors for the management of type-ii diabetes mellitus: Insight into molecular docking and SAR. Curr. Top. Med. Chem. 2024 25 10.2174/0115680266339313241021053225 39484764
    [Google Scholar]
13. Yang X. Jiao Z. Chandarajoti K. Lv S. Ke X. Zhou W. Carboxamide: A privileged pharmacophore for the development of anti-infectious and anti-cancer drugs. Curr. Top. Med. Chem. 2025 25 10.2174/0115680266363457250714113345 40698681
    [Google Scholar]
14. Neha K. Wakode S. Oxazole-based molecules: recent advances on biological activities. Curr. Top. Med. Chem. 2025 25 10.2174/0115680266419594251103103459
    [Google Scholar]
15. Agrawal M. Kumar A. Singh A.K. Singh H. Narasimhan B. Kumar P. Design, synthesis, molecular docking, and biological evaluation of 7-Phenyl-5-(thiophen-2-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones as antibacterial agents. Curr. Top. Med. Chem. 2025 25 10.2174/0115680266355090250407105802 40442910
    [Google Scholar]